# Quality Score Report: ADR-001 NPT-014 Elimination Policy (I2)

## L0 Executive Summary

**Score:** 0.9455/1.00 | **Verdict:** REVISE | **Weakest Dimension:** Evidence Quality (0.93)
**One-line assessment:** ADR-001 I2 closes four of the six I1 gaps with precision, advancing from 0.9185 to 0.9455, but falls 0.0045 short of the C4 threshold (0.95) due to A-31's missing full bibliographic entry and the non-enumeration of R-QE-001 through R-ADS-003; a single targeted fix to A-31's citation resolves the primary gap.

---

## Scoring Context

- **Deliverable:** `projects/PROJ-014-negative-prompting-research/orchestration/neg-prompting-20260227-001/phase-5/ADR-001-npt014-elimination.md`
- **Deliverable Type:** ADR (Architecture Decision Record)
- **Criticality Level:** C4
- **C4 Threshold:** 0.95 (elevated from standard H-13 threshold of 0.92)
- **Scoring Strategy:** S-014 (LLM-as-Judge)
- **SSOT Reference:** `.context/rules/quality-enforcement.md`
- **ADR Gate Checks Applied:** GC-ADR-1 through GC-ADR-5
- **Strategy Findings Incorporated:** Yes -- I1 report (adversary-adr001-i1.md, score 0.9185 REVISE) incorporated as prior context
- **Prior Score (I1):** 0.9185 (trajectory: +0.0270 improvement in I2)
- **Iteration:** I2 (second scoring)
- **Scored:** 2026-02-28T00:00:00Z

---

## Score Summary

| Metric | Value |
|--------|-------|
| **Weighted Composite** | 0.9455 |
| **C4 Threshold** | 0.95 |
| **Standard H-13 Threshold** | 0.92 |
| **Verdict** | REVISE |
| **Distance from C4 Threshold** | 0.0045 |
| **I1 Score** | 0.9185 |
| **Score Delta (I1 -> I2)** | +0.0270 |
| **Strategy Findings Incorporated** | Yes (I1 report) |
| **FMEA Arithmetic Verified** | YES -- all 5 RPN values correct (72, 48, 100, 150, 28) |
| **L2 Token Budget Arithmetic Verified** | YES -- 745/850 = 87.6% correct |

---

## Gate Check Results

| Gate | Description | Status | Evidence |
|------|-------------|--------|----------|
| GC-ADR-1 | Nygard format compliance (Title, Status, Context, Decision, Consequences) | PASS | All 5 required sections present; extended with L0/L1/L2, Forces, Options, Compliance |
| GC-ADR-2 | Evidence tier labels on all claims | PASS WITH MINOR GAP | A-20 and A-15 now have full bibliographic citations (arXiv URLs); A-31 still lacks full bibliographic entry (no author, title, or DOI) |
| GC-ADR-3 | PG-003 reversibility assessment present | PASS | Full 5-component reversibility table; HIGH overall; null-framing contingency documented |
| GC-ADR-4 | Phase 2 dependency correctly handled | PASS | Unconditional status explained with 3 independent sources; "Phase 2 outcome irrelevant" explicitly stated |
| GC-ADR-5 | No false validation claims | PASS | MANDATORY EPISTEMOLOGICAL BOUNDARY maintained; UNTESTED label applied to NPT-009 vs. positive framing; A-11 absent throughout |
| A-11 check | A-11 (hallucinated citation) absent | PASS | Zero occurrences; C-001 constraint entry explicitly prohibits it |
| AGREE-5 check | AGREE-5 not presented as T1/T3 | PASS | Labeled "internally generated, NOT externally validated" at line 64; not cited as peer-reviewed evidence anywhere |

---

## I2 Fix Verification

| I1 Fix Target | Applied in I2? | Evidence | Score Impact |
|---------------|---------------|----------|--------------|
| Full bibliographic citations for A-20 and A-15 | YES | Line 493: Geng et al., AAAI 2026, arXiv:2502.15851; Line 494: Ferraz et al., EMNLP 2024, arXiv:2410.06458; full author lists, titles, venues, URLs | Evidence Quality: 0.90 -> 0.93 |
| Pre-Mortem vs. Consequences:Risks scope distinction | YES | Line 350: scope distinction note at Pre-Mortem header; Line 466: scope distinction note at Risk Register header; explicitly differentiates failure discovery methodology from probability/impact classification | Internal Consistency: 0.91 -> 0.95 |
| Group 2 "27+5=32" breakdown cited, Step 5 connected to H-17 | YES | Line 284: "5 framework-level + 27 agent-level = 32 total" with source "barrier-4/synthesis.md L1 Recommendation Counts table"; Lines 265-269: Step 5 now includes explicit H-17 quality gate hook paragraph referencing NPT-014 diagnostic as validation predicate and FMEA RPN 150 mitigation | Actionability: 0.91 -> 0.94; Traceability: 0.93 -> 0.95 |
| FMEA S/O/D scale definitions added | YES | Line 364: Full paragraph defining 1-anchor, 5-anchor, and 10-anchor for all three dimensions; Detection scale explicitly distinguishes automated gate detection (1) from undetectable production impact (10) | Methodological Rigor: 0.93 -> 0.95 |
| Options scoring basis footnote | YES | Line 194: "Scoring basis" paragraph with explicit 0-3 per dimension, summed and normalized to /10; labeled "architect's synthesis judgment" | Internal Consistency: supports 0.91 -> 0.95 |
| Option 3 "HIGHEST" Phase 2 Compatibility clarified | YES | Line 200: parenthetical "(zero-change avoidance, not positive Phase 2 support)" added to Option 3 HIGHEST entry | Methodological Rigor: supports 0.93 -> 0.95 |

**I1 fixes not applied (lower priority items):**
- A-31 full bibliographic citation (no author/title/DOI added -- remains "A-31, arXiv (preprint)")
- VS-001 through VS-004 individual code disambiguation (grouping unchanged)
- R-QE-001 through R-ADS-003 enumeration in L1 section (referenced by code range, not listed)

---

## Dimension Scores

| Dimension | Weight | Score | Weighted | Evidence Summary |
|-----------|--------|-------|----------|-----------------|
| Completeness | 0.20 | 0.95 | 0.1900 | All Nygard sections + L0/L1/L2 + 4 adversarial strategies + Group 2 source cited; R-QE-001 through R-ADS-003 not enumerated (minor remaining gap) |
| Internal Consistency | 0.20 | 0.95 | 0.1900 | Pre-Mortem/Risk Register scope distinction added to both tables; option scoring basis declared; Group 2 count confirmed as 32 total |
| Methodological Rigor | 0.20 | 0.95 | 0.1900 | FMEA scale definitions added (1/5/10 anchors for S/O/D); Option 3 HIGHEST clarified; all 4 adversarial strategies documented and rigorous |
| Evidence Quality | 0.15 | 0.93 | 0.1395 | A-20 and A-15 now fully cited with arXiv URLs; A-31 still lacks author/title/DOI; VS disambiguation unresolved |
| Actionability | 0.15 | 0.94 | 0.1410 | Step 5 now connected to H-17 and FMEA RPN 150; Group 2 count clarified; R-QE-001 through R-ADS-003 not enumerated (implementer must consult TASK-012) |
| Traceability | 0.10 | 0.95 | 0.0950 | "5 framework-level" sourced to barrier-4/synthesis.md L1 table; option scoring labeled as architect judgment; A-31 traceability gap minor (T3 corroborating only) |
| **TOTAL** | **1.00** | | **0.9455** | |

**H-15 Arithmetic Verification:**
- Completeness: 0.95 x 0.20 = 0.1900
- Internal Consistency: 0.95 x 0.20 = 0.1900; running: 0.1900 + 0.1900 = 0.3800
- Methodological Rigor: 0.95 x 0.20 = 0.1900; running: 0.3800 + 0.1900 = 0.5700
- Evidence Quality: 0.93 x 0.15 = 0.1395; running: 0.5700 + 0.1395 = 0.7095
- Actionability: 0.94 x 0.15 = 0.1410; running: 0.7095 + 0.1410 = 0.8505
- Traceability: 0.95 x 0.10 = 0.0950; running: 0.8505 + 0.0950 = **0.9455** (confirmed)

**Distance from C4 threshold:** 0.95 - 0.9455 = **0.0045**

---

## Detailed Dimension Analysis

### Completeness (0.95/1.00)

**Evidence:**

The ADR I2 addresses all mandatory requirements with depth:

- All five Nygard sections present (Title, Status, Context, Decision, Consequences), extended with L0/L1/L2 levels
- Constraints table: C-001 through C-007 with source citations
- Forces: 4 tensions explicitly reasoned
- Options: 3 options each with steelman, pros, cons, fit with constraints, and score
- Decision with 4-point rationale and alignment table
- L1 Technical: diagnostic filter, 5-step upgrade procedure, 4-group sequencing, Phase 2 baseline protocol, L2 token budget analysis
- L2 Architectural: evolution path, systemic consequences, Pre-Mortem (5 failure modes), FMEA (5 failure modes with now-defined scale), Inversion
- Consequences: 5 positive, 5 negative, 3 neutral, 6 risk register entries
- Compliance: PG-003 reversibility (5-component), evidence tier labels (6 claims), constraint propagation verification (GC-P4-1 through GC-P4-3)
- Related Decisions: 3 downstream ADRs
- References: 13 entries
- PS Integration with key findings for downstream handoff
- Self-Review Checklist: 17 checks

Group 2 breakdown is now sourced (line 284). The 5 framework-level recommendations are explicitly distinguished from the 27 agent-level recommendations and traced to barrier-4/synthesis.md L1 Recommendation Counts table.

**Gaps:**

The 6 specific rule-file upgrade recommendations (R-QE-001 through R-ADS-003) are referenced by code range at line 277 but not enumerated in the ADR body. An implementer executing Group 1 must consult TASK-012 (rules-update-analysis.md) to get the specific targets. This is the one remaining completeness gap.

**Improvement Path:**

Add a compact sub-table in the Group 1 section listing R-QE-001 through R-ADS-003 by ID and one-line description. This eliminates the TASK-012 dependency for Group 1 implementation planning.

---

### Internal Consistency (0.95/1.00)

**Evidence:**

Both I1 consistency gaps are resolved:

1. **Pre-Mortem / Risk Register redundancy:** Line 350 adds an explicit scope distinction note at the Pre-Mortem Analysis header ("This Pre-Mortem table is a failure discovery methodology (S-004)... The Consequences: Risks table below is a formal risk register"). Line 466 adds a matching scope distinction note at the Risk Register header ("This Risk Register classifies implementation risks by probability and impact for prioritization. The Pre-Mortem Analysis... covers the same failure domain from a causal analysis perspective"). Both tables are now intentionally retained with differentiated purposes explicitly documented.

2. **Option scoring scale undefined:** Line 194 adds an explicit scoring basis paragraph: "Scores reflect the architect's synthesis judgment across the three evaluation dimensions (Evidence Alignment, Implementation Risk, Phase 2 Compatibility), each rated 0-3 (0=absent, 1=low, 2=medium, 3=high alignment), summed and normalized to a /10 scale."

The core logical chain remains fully consistent: T1+T3 evidence -> NPT-014 underperforms -> PG-001 unconditional -> Phase 2 irrelevant -> universal policy. This chain is stated in L0, repeated in Context/Evidence Base, reinforced in Decision/Rationale, and validated in Compliance. No contradictions.

**Gaps:**

No remaining consistency gaps identified.

**Improvement Path:**

No improvement needed on this dimension.

---

### Methodological Rigor (0.95/1.00)

**Evidence:**

Both I1 methodological gaps are resolved:

1. **FMEA scale definitions:** Line 364 adds a full scale definition paragraph: "Severity (1-10): 1=negligible impact on framework quality; 5=moderate degradation requiring rework within one sprint; 10=irreversible architectural damage or governance violation. Occurrence (1-10): 1=extremely unlikely (<1% of instances); 5=moderate likelihood (occurs in ~30-50% of instances); 10=near-certain (occurs in >90% of instances). Detection (1-10): 1=immediate detection by automated quality gate or CI check; 5=detectable during manual review but not automated; 10=undetectable until production behavioral impact observed." The individual S/O/D values can now be independently audited. A Detection=2 for Phase 2 baseline contamination can be verified as meaning "nearly immediate detection by the baseline capture protocol," which is appropriate.

2. **Option 3 "HIGHEST" clarification:** Line 200 adds "(zero-change avoidance, not positive Phase 2 support)" parenthetical to the HIGHEST entry. This prevents the misreading that Option 3 has high Phase 2 support value.

All four adversarial strategies remain rigorously applied: S-003 (genuine steelman per option), S-004 (pre-mortem with now-differentiated scope), S-012 (FMEA with now-defined scale), S-013 (inversion with 5 specific consequences). FMEA arithmetic verified correct. L2 budget arithmetic verified correct. Epistemological discipline (MANDATORY EPISTEMOLOGICAL BOUNDARY) maintained throughout.

**Gaps:**

No remaining methodological rigor gaps identified.

**Improvement Path:**

No improvement needed on this dimension.

---

### Evidence Quality (0.93/1.00)

**Evidence:**

The primary I1 gap (T1 anchor bibliographic opacity) is resolved:

- **A-20 (line 493):** "Geng, Li, Mu, Han, Baldwin, Abend, Hovy, Frermann. 'Control Illusion: The Failure of Instruction Hierarchies in Large Language Models.' AAAI 2026 Main Technical Track. [arXiv:2502.15851](https://arxiv.org/abs/2502.15851)" -- full author list, title, venue, arXiv URL. The paper can now be independently verified without accessing upstream barrier files. The body citation at line 90-91 and the evidence base table at line 90 both reference this consistently.

- **A-15 (line 494):** "Ferraz, Mehta, Lin, Chang, Oraby, Liu, Subramanian, Chung, Bansal, Peng. 'LLM Self-Correction with DeCRIM.' EMNLP 2024 Findings. [arXiv:2410.06458](https://arxiv.org/abs/2410.06458)" -- full author list, title, venue, arXiv URL. The specific claim ("+7-8% compliance improvement") is now anchored to specific sub-claims in the citation description: "+7.3% (RealInstruct) and +8.0% (IFEval) via constraint decomposition; GPT-4 fails constraints on 21%+ of instructions."

Evidence tier assignments remain correct and consistent: T1 for peer-reviewed, T3 for preprint, T4 for observational/compiled, UNTESTED for the Phase 2 framing question. A-11 is absent. AGREE-5 is not presented as T1/T3.

**Gaps:**

1. **A-31 bibliographic incompleteness.** Line 495 still reads: "A-31, arXiv (preprint) | T3 preprint | Corroborating evidence across task types." No author, title, or arXiv URL is provided. Per the rubric's 0.9+ criterion ("all claims with credible citations"), this is a real gap: a T3 claim-supporting source is not independently verifiable without accessing upstream barrier-1 survey files. A-31 is a corroborating rather than primary source, but the rubric does not exempt corroborating sources from citation completeness.

2. **VS-001 through VS-004 code disambiguation.** Line 497 still groups VS-001 through VS-004 as a single reference entry. The body of the ADR cites VS-001 (line 94) and VS-003 (line 95) individually. A reader cannot distinguish what VS-001 vs. VS-003 represent from the References section alone.

The A-31 gap is the primary evidence quality remaining issue.

**Improvement Path:**

Add full bibliographic entry for A-31 to the References table (author, title, arXiv identifier). Since A-31 corroborates A-20 and A-15 findings, its citation likely appears in the barrier-1 survey files. Retrieve and add the full citation. Optionally disambiguate VS-001 (33-instance NEVER/MUST NOT catalog) from VS-003 (HARD tier vocabulary observation) in a parenthetical.

---

### Actionability (0.94/1.00)

**Evidence:**

The two primary I1 actionability gaps are resolved:

1. **Group 2 count clarification (line 284):** "TASK-011 produced 32 recommendations across 9 agent families (barrier-4/synthesis.md L1 Recommendation Counts table). Of these 32, 5 are framework-level recommendations targeting the `agent-development-standards.md` guardrails template and constitutional compliance patterns shared across all agents, and 27 are agent-level recommendations targeting specific agent definition files." The arithmetic is now explicit (5+27=32) and the source for the breakdown is cited (barrier-4/synthesis.md L1 Recommendation Counts table). An implementer knows the 5 framework-level recommendations target agent-development-standards.md specifically.

2. **Step 5 quality gate hook (lines 265-269):** "Quality gate hook: This validation step MUST be integrated into the H-17 quality scoring process. The NPT-014 diagnostic filter (above) serves as the validation predicate: any constraint failing the diagnostic is a measurable defect under S-014 (LLM-as-Judge). This closes the loop with the FMEA mitigation for 'New NPT-014 introduction' (RPN 150): the quality gate prevents new NPT-014 instances from passing review." This closes the implementation loop that I1 identified as missing.

Remaining actionability: diagnostic filter (binary, implementable), 5-step procedure (complete), 4-group sequencing (clear order with rationale and counts), Phase 2 baseline protocol (4 numbered steps), L2 budget analysis, FMEA and Pre-Mortem mitigations, Next Agent Hint.

**Gaps:**

1. **R-QE-001 through R-ADS-003 not enumerated.** Line 277 states "TASK-012 identified 6 specific upgrade recommendations (R-QE-001 through R-ADS-003)" and directs the implementer to TASK-012 for the specific targets. The code range is given but the individual recommendations are not listed in the ADR. An implementer of Group 1 must consult a separate document (rules-update-analysis.md) to know which 6 rule files need upgrading. This is a real but bounded actionability gap -- the pointer to TASK-012 is explicit and specific.

**Improvement Path:**

Add a compact sub-table listing R-QE-001 through R-ADS-003 by ID, target file, and one-line description. This converts the Group 1 implementation section from "consult TASK-012" to self-contained.

---

### Traceability (0.95/1.00)

**Evidence:**

Both I1 traceability gaps are resolved:

1. **"5 framework-level" source (line 284):** Now explicitly traced to "barrier-4/synthesis.md L1 Recommendation Counts table." An implementer can verify the 32-recommendation total and the 5/27 breakdown by reading this specific section of the synthesis document.

2. **Option scoring rubric (line 194):** Now labeled "architect's synthesis judgment across the three evaluation dimensions." This honest acknowledgment that the 9/10, 6/10, 3/10 scores are qualitative synthesis (not derived from an upstream quantitative model) resolves the traceability gap by being transparent about the evaluative nature of these scores.

All major claims trace to specific sources: PG-001 -> barrier-2/synthesis.md ST-4; 22 NPT-014 instances -> TASK-012; 130 total recommendations -> barrier-4/synthesis.md L0; 5-domain universal NPT-014 presence -> barrier-4/synthesis.md Themes 1 and 2; Phase 2 unconditional exception -> barrier-4/synthesis.md Section 3 (quoted). Constraint table (C-001 through C-007) has source citations. Evidence tier table maps claims to tiers and sources. PS Integration provides worktracker linkage.

**Gaps:**

1. **A-31 traceability.** A-31's citation at line 495 lacks an arXiv identifier. An independent verifier cannot trace this source without accessing upstream barrier-1 files. This is a minor but real traceability gap. A-31 is T3 corroborating evidence, not a primary claim anchor, which limits the impact.

This gap does not prevent 0.95 on the Traceability dimension specifically, because (a) the primary traceability chains through A-20 and A-15 (the T1 anchors) are now fully traceable with arXiv URLs, (b) all major claims are traced to specific documents with version numbers, and (c) the T3 corroborating source's absence is bounded and acknowledged rather than concealed.

**Improvement Path:**

Add the arXiv identifier for A-31 to complete the reference table. This is the same fix that would improve Evidence Quality -- one fix resolves both dimensions' remaining gap.

---

## Improvement Recommendations (Priority Ordered)

| Priority | Dimension | Current | Target | Recommendation |
|----------|-----------|---------|--------|----------------|
| 1 | Evidence Quality | 0.93 | 0.95 | Add full bibliographic entry for A-31: author(s), title, arXiv identifier. Retrieve from barrier-1 survey files (where A-31 was first catalogued). This single fix addresses the only remaining gap blocking the 0.95 threshold -- it affects both Evidence Quality and Traceability dimensions simultaneously. |
| 2 | Actionability | 0.94 | 0.95 | Add a compact sub-table in the Group 1 section listing R-QE-001 through R-ADS-003 by ID, target rule file, and one-line description. Eliminates the TASK-012 dependency for Group 1 implementation. |
| 3 | Evidence Quality | 0.93 | 0.94 | Add parenthetical disambiguation for VS-001 through VS-004 in References entry: "VS-001: 33-instance NEVER/MUST NOT/FORBIDDEN/DO NOT catalog; VS-003: HARD tier vocabulary as structured negative vocabulary observation." |

**Score impact estimate:** Fix #1 alone (A-31 full citation) would raise Evidence Quality from 0.93 to approximately 0.95, increasing the weighted composite by 0.003 (0.02 improvement x 0.15 weight). Combined with Fix #2 raising Actionability from 0.94 to 0.95 (0.01 x 0.15 = 0.0015), the total composite improvement would be approximately +0.0045, reaching **0.9500** exactly. Both fixes together close the gap precisely.

---

## ADR-Specific Gate Check Summary

| Gate | Check | Result | Notes |
|------|-------|--------|-------|
| GC-ADR-1 | Nygard format complete | PASS | Title, Status, Context, Decision, Consequences all present; extended format |
| GC-ADR-2 | Evidence tier labels present | PASS WITH MINOR GAP | A-20/A-15 now fully cited with arXiv URLs; A-31 lacks author/title/arXiv identifier |
| GC-ADR-3 | PG-003 reversibility documented | PASS | Full 5-component table; HIGH overall; PG-003 null-framing contingency present |
| GC-ADR-4 | Phase 2 dependency handled | PASS | Unconditional status explained with 3 independent citations; "Phase 2 outcome irrelevant" explicitly stated |
| GC-ADR-5 | No false validation claims | PASS | MANDATORY EPISTEMOLOGICAL BOUNDARY enforced; UNTESTED labels applied; A-11 absent |

---

## Leniency Bias Check

- [x] Each dimension scored independently before composite computed
- [x] Evidence documented for each score -- specific line numbers and content cited
- [x] Uncertain scores resolved downward: Evidence Quality held at 0.93 (not 0.95) despite strong T1 improvements, because A-31 bibliographic incompleteness is a real gap under the rubric's "all claims with credible citations" criterion
- [x] Uncertain scores resolved downward: Actionability held at 0.94 (not 0.95) because R-QE-001 through R-ADS-003 non-enumeration is a real gap requiring external document consultation
- [x] C4 threshold (0.95) held firm -- score of 0.9455 is correctly below threshold
- [x] No dimension scored above 0.95 -- three dimensions at 0.95, two below
- [x] I2 trajectory improvement verified: 0.9185 -> 0.9455 (+0.0270) is consistent with 4 targeted fixes applied
- [x] FMEA arithmetic independently verified: 4x6x3=72, 8x3x2=48, 5x5x4=100, 6x5x5=150, 7x2x2=28 -- all correct
- [x] L2 token budget arithmetic independently verified: 745/850 = 87.647% confirmed within ceiling
- [x] A-11 absence confirmed: zero occurrences in ADR body
- [x] AGREE-5 over-citation checked: correctly labeled "internally generated, NOT externally validated" at line 64; not cited as T1/T3 anywhere
- [x] MUST NOT instructions honored: A-11 not accepted; AGREE-5 not accepted as T1/T3; leniency not applied

---

## Session Context (Handoff Schema)

```yaml
verdict: REVISE
composite_score: 0.9455
threshold: 0.95
standard_threshold: 0.92
weakest_dimension: Evidence Quality
weakest_score: 0.93
critical_findings_count: 0
iteration: 2
prior_score: 0.9185
score_delta: +0.0270
distance_from_threshold: 0.0045
top_gap_dimensions:
  - "Evidence Quality (0.93): A-31 lacks author/title/arXiv identifier; VS-001 through VS-004 not individually disambiguated"
  - "Actionability (0.94): R-QE-001 through R-ADS-003 not enumerated; implementer must consult TASK-012 for Group 1 specifics"
improvement_recommendations:
  - "Add full bibliographic entry for A-31 (author, title, arXiv ID) to References table -- single fix closes ~0.003 of the 0.0045 gap"
  - "Add compact sub-table of R-QE-001 through R-ADS-003 (ID, target file, description) in Group 1 section"
  - "Optionally disambiguate VS-001 vs. VS-003 in References entry parenthetical"
gate_checks_passed: [GC-ADR-1, GC-ADR-3, GC-ADR-4, GC-ADR-5]
gate_checks_with_minor_gap: [GC-ADR-2]
blocking_findings: none
arithmetic_verified: true
i1_fixes_applied: [A-20_full_citation, A-15_full_citation, pre_mortem_scope_distinction, risk_register_scope_distinction, group2_count_sourced, step5_h17_hook, fmea_scale_definitions, options_scoring_basis, option3_highest_clarified]
i1_fixes_not_applied: [A-31_full_citation, VS_disambiguation, R_QE_001_enumeration]
```

---

*Scored by: adv-scorer*
*Strategy: S-014 (LLM-as-Judge, 6-dimension weighted composite)*
*Criticality: C4 (threshold 0.95)*
*SSOT: `.context/rules/quality-enforcement.md`*
*Workflow: neg-prompting-20260227-001*
*Task: TASK-016 (phase-5 ADR scoring, I2)*
*Created: 2026-02-28*
